These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Bilban M; Heintel D; Scharl T; Woelfel T; Auer MM; Porpaczy E; Kainz B; Kröber A; Carey VJ; Shehata M; Zielinski C; Pickl W; Stilgenbauer S; Gaiger A; Wagner O; Jäger U; Leukemia; 2006 Jun; 20(6):1080-8. PubMed ID: 16617321 [TBL] [Abstract][Full Text] [Related]
6. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. Mátrai Z; Andrikovics H; Szilvási A; Bors A; Kozma A; Ádám E; Halm G; Karászi É; Tordai A; Masszi T Pathol Oncol Res; 2017 Jan; 23(1):165-171. PubMed ID: 27757836 [TBL] [Abstract][Full Text] [Related]
8. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia. Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419 [TBL] [Abstract][Full Text] [Related]
9. The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia. Kaderi MA; Murray F; Jansson M; Merup M; Karlsson K; Roos G; Aleskog A; Tobin G Leuk Res; 2008 Jun; 32(6):984-7. PubMed ID: 18006055 [TBL] [Abstract][Full Text] [Related]
10. LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations. Kristensen L; Kristensen T; Abildgaard N; Royo C; Frederiksen M; Mourits-Andersen T; Campo E; Møller MB Eur J Haematol; 2016 Aug; 97(2):175-82. PubMed ID: 26558352 [TBL] [Abstract][Full Text] [Related]
11. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. van't Veer MB; Brooijmans AM; Langerak AW; Verhaaf B; Goudswaard CS; Graveland WJ; van Lom K; Valk PJ Haematologica; 2006 Jan; 91(1):56-63. PubMed ID: 16434371 [TBL] [Abstract][Full Text] [Related]
12. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Stamatopoulos B; Meuleman N; Haibe-Kains B; Duvillier H; Massy M; Martiat P; Bron D; Lagneaux L Clin Chem; 2007 Oct; 53(10):1757-66. PubMed ID: 17702857 [TBL] [Abstract][Full Text] [Related]
13. Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients. Van Damme M; Crompot E; Meuleman N; Mineur P; Dessars B; El Housni H; Bron D; Lagneaux L; Stamatopoulos B Epigenetics; 2014 Oct; 9(10):1374-81. PubMed ID: 25437053 [TBL] [Abstract][Full Text] [Related]
14. LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. Kaderi MA; Kanduri M; Buhl AM; Sevov M; Cahill N; Gunnarsson R; Jansson M; Smedby KE; Hjalgrim H; Jurlander J; Juliusson G; Mansouri L; Rosenquist R Haematologica; 2011 Aug; 96(8):1153-60. PubMed ID: 21508119 [TBL] [Abstract][Full Text] [Related]
15. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status. Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689 [TBL] [Abstract][Full Text] [Related]
16. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084 [TBL] [Abstract][Full Text] [Related]
17. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Maloum K; Settegrana C; Chapiro E; Cazin B; Leprêtre S; Delmer A; Leporrier M; Dreyfus B; Tournilhac O; Mahe B; Nguyen-Khac F; Lesty C; Davi F; Merle-Béral H Ann Hematol; 2009 Dec; 88(12):1215-21. PubMed ID: 19340428 [TBL] [Abstract][Full Text] [Related]
18. Association of lipoprotein lipase expression with TP53 gene polymorphisms in chronic lymphocytic leukemia cells. Abramenko I; Bilous N; Chumak A; Dyagil I; Martina Z Exp Oncol; 2021 Sep; 43(3):224-228. PubMed ID: 34591432 [TBL] [Abstract][Full Text] [Related]
19. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263 [TBL] [Abstract][Full Text] [Related]
20. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients. Meuleman N; Stamatopoulos B; Dejeneffe M; El Housni H; Lagneaux L; Bron D Leukemia; 2008 Oct; 22(10):1882-90. PubMed ID: 18633433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]